Abstract:Managing Intellectual Property (IP) protection over test data is a growth strategy in the trade competition, embodied as one of the crucial topics of US-China trade negotiations. Accordingly, the US took the trade war as a tool for the rivalry in the pharmaceutical industry and furnishing domestic companies with better protection schemes and more symmetrical access to the Chinese market. Even though the Economic and Trade Agreement Between the Government of the United States of America and the Government of the People’s Republic of China (Phase-one Trade Agreement) quelled the trade war, the dualism protection mechanism – ‘confidential business information’ protection and data exclusivity rules for pharmaceutical test data warrants exploring the legal basis and practical reasons. This article explores and clarifies the China and US trade arguments on test data and specific provisions of the Phase-one Trade Agreement from both empirical and normative perspectives. The empirical study sheds light on the pharmaceutical market competition between the US and China. Then it assesses the test data protection under the Phase-one Trade Agreement in light of US free trade agreements (FTAs), domestic legislation, and the Chinese test data protection legal system. In addition to providing contextual reflections, this article proposes China-US further negotiation for test data protection from a public health-friendly perspective, considering the US and Chinese legal frameworks and priorities regarding pharmaceuticals. Pharmaceutical, intellectual property, test data, confidential business information, data exclusivity, public health, US-China trade war, foreign trade agreements, Phase-one Trade Agreement

Analysis of the Protection to Marketing Approval Data under the TRIPS Agreement

Influences on Selection Policies of Agriculture Protection for Entry WTO

Comparative Study on Pharmaceutical Data Protection System of China and Japan

TRIPS and Developing Countries

On the Trade Dispute Derived from the Hidden Trouble of the Security of GMOs and the Countermeasures of China

Protectionism in the Era of Globalisation: The Misuse of Anti-Dumping Instruments From an EU Perspective.

Analysis on TRIPS-Plus Obligations of the TPP IP Clauses

A Legal Analysis on the Current Trade Status of Traditional Chinese Medicinal Product in the E.U. — From the Perspectives of WTO Law and E.U. Pharmaceutical Law

Analysis of Injury to Agriculture of Unfair Intellectual Property Protection towards Farm Produce in China

Technical Barriers and Trade Protection

No Country is an Island in Regulating Food Safety:How the WTO Monitors Chinese Food Safety Laws Through the Trade Policy Review Mechanism（TPRM）

Analysis of Protecting for Chinese Medical and Pharmaceutical Intellectual Property

Intellectual Property Rights Protection and Sino-U.S.Bilateral Trade Issues

Introduction and Profound Consideration on Intellectual Property Rights Protection Standard Terms Relat-ed to Drugs beyond the Regulations of TRIPS

TRIPS-plus and Access to Medicines in China.

Content Analysis of TMT Notification in the Field of Medical Cosmetics among WTO Membership

Rethinking Test Data Protection in China-US Trade War: Integrating Empirical and Normative Analysis

The impact of intellectual property articles on the quality of export products: Based on text analysis of China's trade agreements

A Legal and Economic Analysis of the Trade Secrecy Regime

TRIPS Agreement and Public Health

Trade Mark Restrictions under the TRIPS Agreement: The WTO Panel Findings on Australia’s Tobacco Plain Packaging Legislation